Stock data
| Market cap. | £106.2m |
| Last close | 169.00p |
| High / Low (52 weeks) | 176.2p / 115.2p |
| Stock market listing | FULL |
| Forecast net debt (m) | N/A |
| Forecast gearing ratio (%) | N/A |
| Team | Investment Companies & Trusts |
| Sector | Investment Trusts |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (7.74) | 0.63 | 38.2 |
| Relative * | 3.95 | 20.86 | 17.41 |
* % Relative to local index
Other companies covered in sector
Latest research
Outperformance over the long term
Review | Investment Trusts | 10/11/2011
Uplift potential for biotech sector
Review | Investment Trusts | 11/03/2011
A consistently strong performance with further growth potential
Review | Investment Trusts | 21/07/2010
Fund raising to build on consistently strong performance
Update | Investment Trusts | 30/09/2009
Investment summary
During the past 12 months The Biotech Growth Trust’s (BIOG) share price and NAV have risen by 5.9% and 10.8% respectively. It has outperformed its benchmark, the NASDAQ Biotechnology Index (sterling adjusted), by 1.1% in terms of NAV total return and underperformed by 3.8% in terms of share price total return during the past year. BIOG has a long-term record of outperformance against both broader biotech benchmarks and the FTSE All-Share. Over the next six months, there are a number of significant regulatory decisions and pivotal trial results that the manager believes will create value and drive momentum. Healthcare and large-cap pharma companies still seek to replenish their product pipelines and, with valuations at 15-year lows, the outlook for M&A is positive.
Last updated on 10/11/2011
Key management
| John Sclater, Chairman |
| Richard Klemm, Fund manager |
| Geoffrey Hsu, Fund manager |
Company address
| One Wood Street London EC2V 7WS United Kingdom View website |
